Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

Autologous haematopoietic stem cell transplantation, or aHSCT for short, is usually used to treat blood cancers, and involves harvesting stem cells from the person’s own bone marrow or blood followed ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

The singer shares how a new treatment for multiple sclerosis has helped him hit the road for the band's 30th anniversary tour ...

Multiple sclerosis (MS) is a chronic autoimmune, neurodegenerative disease that attacks the central nervous system (CNS). These attacks lead to the breakdown of myelin, the protective cover that ...

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...